Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

abine for five days.

Preliminary data for this trial were previously announced at the American Society of Hematology Annual Meeting in December 2007.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 "Copay coupons," ... sales of brand drugs among patients with prescription drug ... to a new report  from the Department ... Inspector General (OIG). Federal anti-kickback laws prohibit suppliers ... are subsidized by the federal government. ...
(Date:9/19/2014)... DUBLIN , September 19, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/s6g5wm/global ) has announced the addition of ... report to their offering. ... devices have been broadly classified into wide ... are used for the treatment of different ...
(Date:9/19/2014)... 19, 2014  4WEB Medical announces the formal launch ... ankle osteotomy implants on the market today at ... meeting in Chicago .  The Osteotomy ... osteotomy needs with 74 size options included in one ... of only 15 to 18 implant sizes, which limited ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 34WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... WOONSOCKET, R.I. , July 30 MultiCell Technologies, Inc. ... fresh new look and updated information about discovery technology platforms and ... common questions. , , ... "The new website is designed to inform our shareholders, scientists and ...
... July 29 As of late, the most prominently ... Lap-Band procedure, a minimally invasive operation in which an adjustable ... in order to restrict food capacity and promote weight loss. ... Lap Band surgery without the use of the band ...
Cached Medicine Technology:MultiCell Technologies Launches New Web Site 2MultiCell Technologies Launches New Web Site 3Sleeve Gastrectomy Procedure With Dr. Michael Feiz Serves as a Highly Effective Alternative to Lap Band Surgery 2Sleeve Gastrectomy Procedure With Dr. Michael Feiz Serves as a Highly Effective Alternative to Lap Band Surgery 3
(Date:9/21/2014)... new study of cancer patients who smoke, those using ... dependent and equally or less likely to have quit ... Cancer , a peer-reviewed journal of the American ... benefits of e-cigarettes for helping cancer patients give up ... all cancer patients who smoke should be advised to ...
(Date:9/21/2014)... UNIWIGS, one of the leading online stores of ... offers a line of human hair lace wigs inspired by ... shows people what the latest celebrity hairstyles are. ... are 4 different hairstyles to choose from: a style of ... wigs and a hot ombre red lace wig. People can ...
(Date:9/21/2014)... September 21, 2014 Hastings and Hastings, ... announces record demand for aggressively discounted accident victim attorney’s ... throughout the Valley each year, it is more important ... to discounted attorney’s fees as a way to enjoy ... Hastings has been a frontrunner when it comes to ...
(Date:9/21/2014)... 2014 More than a quarter of house ... start in one of two ways. The first type of ... The second type of dryer fire occurs when lint builds ... also catch fire due to malfunctioning electrical systems so if it ... a look!) Here are some ways that you can prevent ...
(Date:9/21/2014)... trigger an allergy to peanuts than raw peanuts, suggests ... say that specific chemical changes caused by the high ... the body,s immune system, ,priming, the body to set ... sees any peanuts. , The results might explain the ... in the Western world compared to populations in East ...
Breaking Medicine News(10 mins):Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:UniWigs New Arrivals Just In- Human Hair Lace Wigs Inspired By Famous Celebrities 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 3Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:Dry roasting could help trigger peanut allergy 2
... Scottish ministers have announced a ?4 million cash boost to fight ... cash is expected to go towards stemming Scotland's high rates of ... sufferers. ,It has been estimated that about 20,000 people ... to be a "silent killer" among Scotland's drug users - in ...
... from the University of Newcastle, UK, a drug used ... the damage caused in cirrhosis of the liver.// ... scarring linked with cirrhosis is irreversible, the recent study ... by using Sulphasalazine.,Heavy drinking and obesity has resulted in ...
... reliable tests to detect early stages of cancerous growth in ... colon cancers successfully//, is often a procedure associated with a ... by going through this procedure to rule out or confirm ... fear of the discomfort they may have to go through. ...
... the young, so all anti-binge drinking sermons are by default ... fence//, it has come to light that the fifty and ... of drinks, to the extent of causing irreparable damage to ... can cause damage to the liver and brain. ...
... A new study says that uterine cancer is more lethal ... found that black women// with uterine cancer survived for 10.2 ... the same treatment. ,Dr. G. Larry Maxwell and his ... said black women were 26 percent more likely to die ...
... those who feel low during these nine months should seek ... Tommy's Baby Charity here surveyed 1,000 women about how they ... ,The survey found that three in five women ... Two thirds felt even more exhausted than they expected and ...
Cached Medicine News:Health News:Scotland’s Fight against Hepatitis C Boosted by ? 2
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: